Global Antimicrobial Susceptibility Testing Market Size, Share, Growth Analysis, By Test type(Phenotypic testing, genotypic testing), By End user(Hospitals and diagnostic laboratories, research and academic institutes), By Product type(Instruments, reagents and kits) - Industry Forecast 2024-2031

Global Antimicrobial Susceptibility Testing Market size was valued at USD 3.60 Billion in 2022 and is poised to grow from USD 3.79 Billion in 2023 to USD 5.68 Billion by 2031, at a CAGR of 5.20% during the forecast period (2024-2031).

Global Antimicrobial Susceptibility Testing (AST) Market features a competitive landscape with several prominent players vying for market share. Key companies operating in the market are actively engaged in research and development activities to introduce advanced AST systems and technologies. Strategic collaborations, partnerships, and acquisitions are common strategies employed by these players to expand their product portfolio and strengthen their market presence. The market is characterized by intense competition, with a focus on innovation, cost-effectiveness, and accuracy of AST solutions. The presence of established players with strong distribution networks and brand recognition presents barriers to entry for new entrants. 'Thermo Fisher Scientific Inc. (US)', 'Bio-Rad Laboratories, Inc. (US)', 'Danaher Corporation (US)', 'Becton, Dickinson and Company (US)', 'bioMérieux SA (France)', 'Roche Diagnostics (Switzerland)', 'Abbott Laboratories (US)', 'Bruker Corporation (US)', 'Merck KGaA (Germany)', 'Agilent Technologies, Inc. (US)', 'ConvaTec Group plc (UK)', 'Cepheid (US)', 'HiMedia Laboratories Pvt. Ltd. (India)', 'Liofilchem s.r.l. (Italy)', 'Accelerate Diagnostics, Inc. (US)', 'Creative Diagnostics (US)', 'Bio-Rad Laboratories (US)', 'Synbiosis (UK)', 'ELITechGroup (France)', 'QIAGEN N.V. (Germany)'

The rise in antimicrobial resistance is a significant driver for the AST market. The emergence of drug-resistant pathogens poses a severe threat to public health globally. For instance, the increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has created a dire need for accurate AST to guide clinicians in selecting appropriate antibiotics for treatment.

Integration of artificial intelligence (AI) and machine learning: The integration of AI and machine learning algorithms in AST data analysis is a growing trend. These technologies can assist in the interpretation of complex datasets and improve the accuracy and speed of AST results interpretation. For example, the AI-powered platform DeepAMR uses machine learning to predict bacterial susceptibility to antibiotics based on genomic data.

North America dominated the global AST market, accounting for a substantial market share. The region's dominance can be attributed to several factors, including advanced healthcare infrastructure, well-established laboratory networks, and a strong focus on research and development activities. North America is home to prominent market players, such as bioMérieux, Thermo Fisher Scientific, and BD, which contribute to the region's market leadership. Additionally, the high prevalence of antimicrobial resistance and the proactive measures taken by healthcare organizations to address the issue drive the adoption of AST technologies in the region. With supportive government initiatives, strong investments in healthcare, and a growing emphasis on patient safety, North America holds a significant market share in the global AST market.